Table 4

Summary of 3 included synbiotic studies
Probiotic studies Location Inclusion criteria Treatment used in study groups, n = Treatment duration Reported Outcomes
Chouraqui 200824 France (Marseille) 37 – 42 weeks, gestation, ≤ 14 days singletons, 2500 – 4500g birth weight 1) Probiotic group: Bifibacterium Longum BL999 1.29 × 108 cfu/100 ml formula, L.Rhamnosus 6.45 × 108 cfu/100 ml formula, n=60 4 months, observation: 16 – 52 weeks Growth: Length, Head circumference Stool frequency, consistency, Incidence of diarrhea during treatment period Frequency of infections
2) Synbiotic group 1: Bifibacterium.Longum BL999 1.29 × 108 cfu/100 ml, L Rhamnosus 6.45 × 108 cfu/100 ml, 90% GOS, 10% ScFOS 0.4 g/100 ml n=54
3) Synbiotic group 2: Bifibacterium Longum BL999 2.58 × 108 cfu/100 ml, LParacasei 2.58 × 108 cfu/100 ml, 90% GOS, 10% ScFOS 0.4 g/100 ml, n=60
4) Placebo group: Conventional infant formula no probiotic or prebiotic, n=53
Puccio 200725 Palermo Italy Healthy Full term infants with gestational age 39 weeks 1) Synbiotic group: Bifibacterium Longum BL 999 2 × 107 Cfu/g powder, GOS 90% FOS 10% at 4g/L, n=42, n=67 112 days Growth: Weight, length, head circumference
Stool frequency (evacuations/day)
2) Conventional infant formula no synbiotic, n=55
Crying, restlessness, colic, spitting and vomiting
Volume of feed tolerated
Frequency of respiratory tract infections
Vlieger 200921 Niewegein, Netherlands Healthy Full term infants with gestational age > 37 weeks, < 7 days, formula fed 1) Synbiotic group: Bifibacterium animalis ssp Lactis 1 × 107 Cfu/g powder, Lactobacillusn paracasei 1 × 107 Cfu/g powder, GOS 0.24 g/100 ml, n=67 6 months Growth: Weight, length, head circumference
2) Placebo group: Prebiotic infant formula GOS 0.24 g/100 ml, n=59

Mugambi et al.

Mugambi et al. Nutrition Journal 2012 11:81   doi:10.1186/1475-2891-11-81

Open Data